Wednesday , March 29 2017
Home / Autoimmune Disorders

Autoimmune Disorders

FDA Approves Genentech’s Ocrevus for Relapsing and Primary Progressive Forms of Multiple Sclerosis

South San Francisco, CA — March 28, 2017 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis. The …

Read More »

FDA Grants Breakthrough Therapy Designation to Genentech’s Rituxan for Treatment of Pemphigus Vulgaris

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to Rituxan® (rituximab) for pemphigus vulgaris, a rare, serious and life-threatening condition characterized by progressive painful blistering of …

Read More »

Apitope’s Multiple Sclerosis Drug Demonstrates Positive Results in its Phase IIa Study

Hasselt, Belgium and Chepstow, UK: 21 February 2017 − Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, announces positive results from the Phase IIa clinical study of its lead product candidate, ATX-MS-1467, for the treatment of patients with multiple sclerosis. The Phase …

Read More »

Celgene to Acquire Autoimmune Disease Startup Delinia

SUMMIT, N.J. & CAMBRIDGE, Mass.–(BUSINESS WIRE)– Celgene Corporation (NASDAQ: CELG) and Delinia, Inc. (“Delinia”), a privately held biotechnology company developing novel therapeutics for autoimmune diseases, today announced that they have entered into an agreement for the acquisition of Delinia by Celgene. The transaction expands Celgene’s Inflammation and Immunology pipeline through …

Read More »

FDA Grants Priority Review to Genentech’s Actemra for Giant Cell Arteritis

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Supplemental Biologics License Application (sBLA) for Actemra® (tocilizumab) for the treatment of GCA, a chronic, potentially life-threatening autoimmune condition. The …

Read More »

Celgene Obtains Option to Acquire Autoimmune Disease Company Anokion

LAUSANNE, Switzerland & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anokion, a privately held biopharmaceutical company developing novel tolerance-inducing therapeutics for autoimmune diseases, today announced the formation of an exclusive global research collaboration with Celgene Switzerland LLC, an affiliate of Celgene Corp. Under the terms of the collaboration agreement, Anokion received a $45 million upfront …

Read More »

CSL and Momenta Announce Collaboration and License Agreement to Develop Fc Multimer Programs

CAMBRIDGE, MA — Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) and CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that they have entered into an exclusive research collaboration and worldwide license agreement to develop and commercialize Fc multimer proteins, including Momenta’s M230, a selective immunomodulator of Fc receptors, which is expected to enter the clinic …

Read More »

Jounce Therapeutics Files for $75M IPO

CAMBRIDGE, Mass., January 3, 2017 –Jounce Therapeutics, a clinical-stage immuno-oncology company, has filed an initial public offering  through which it hopes to raise $75 million in 2017. The Cambridge, MA-based company was founded in 2012 and employs a two-pronged approach to therapy development: using a translational science platform that targets …

Read More »

Lycera’s RORgamma Agonist to Begin Phase 1 Trials

NEW YORK and ANN ARBOR, Mich., January 4, 2017 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the initiation of a Phase 1/2a clinical trial of the Company’s novel immuno-oncology therapeutic candidate LYC-55716, in patients with advanced, relapsed, or refractory solid tumors. “We …

Read More »

Investigating Kidney Biomarkers to Track Lupus

ANN ARBOR, Mich. – Lupus, a chronic autoimmune disease, can wreak havoc on an affected individual’s body through inflammation, pain and even damage of the skin, joints and organs. To try to better understand how the disease begins and progresses, researchers at the University of Michigan investigated whether kidney biomarkers …

Read More »